珠海市人民医院医疗集团子宫内膜异位症推荐专家

简介:

珠海市人民医院，暨南大学附属珠海医院，是一所历史悠久、技术精湛的三甲医院。医院秉承“人民医院为人民”的宗旨，致力于为患者提供优质的医疗服务。医院设有介入诊疗中心、精准医学诊疗中心等特色科室，其中介入诊疗中心是全国综合介入主委单位，具有国内领先的介入治疗技术，特别是在子宫内膜异位症等妇科疾病的治疗方面具有显著优势。医院精准医学诊疗中心依托珠海市人民医院搭建，与澳门大学共建，开展肿瘤个体化免疫治疗等研究，为子宫内膜异位症等疾病提供精准诊疗方案。医院致力于打造医疗高地和粤港澳国际大湾区国际医疗中心，为广大患者提供全方位、高质量的医疗服务。子宫内膜异位症（endometriosis）是指有活性的内膜细胞种植在子宫内膜以外的位置而形成的一种女性常见妇科疾病。内膜细胞本该生长在子宫腔内,但由于子宫腔通过输卵管与盆腔相通,因此使得内膜细胞可经由输卵管进入盆腔异位生长。，子宫内膜种植,免疫防御功能缺陷,遗传与体质的因素,内分泌功能失调，盆腔，子宫内膜异位症的治疗方案,因病情的轻重,患者的年龄和生育情况而有所不同。如病情较重,或表现为重的痛经,或盆腔检查发现有肯定的内膜异位结节,就必须采取药物或手术治疗，卵巢恶性肿瘤、盆腔炎性肿块和子宫腺肌病，尽量少吃含有雌激素的食物,如大豆、洋葱、黑米、小麦等，B型超声检查,腹腔镜检查,实验室检查，。

true 左艳主任医师

三级甲等珠海市人民医院医疗集团

好评率：- 接诊量：- 平均响应：-

在三级甲等医院妇科工作二十余年，我院妇科目前为集医疗、教学、科研为一体的重点临床专科，国家公立医院绩效考核排名位居广东省前列，珠海市综合三甲医院技术排名首位。是广东省临床重点专科建设单位，广东省子宫内膜疾病管理联盟牵头单位及珠海市妇科医疗质量控制中心。拥有三大国家级中心：国家级宫颈癌规范诊疗质量控制试点中心、国家级卵巢癌规范诊疗质量控制试点中心、国家级妇科内镜医师培训基地。本人对妇科所有良性肿瘤、恶性肿瘤（子宫颈癌、卵巢癌，子宫内膜癌）、内分泌失调，妇科炎性疾病，不孕症，急腹症等所有妇科疾病诊治经验丰富，尤其擅长盆底功能障碍性疾病（子宫脱垂，阴道前后壁脱垂，尿失禁）的诊治，擅长妇科所有路径的手术，包括多孔或单孔达芬奇机器人手术、多孔或单孔普通腹腔镜、宫腔镜、经阴道手术、开腹手术。擅长应用或不应用网盘植入的各种盆底重建的手术，熟练掌握各种抗压力性尿失禁术式，对结扎后输卵管复通手术经验丰富，熟练掌握子宫颈癌预防、早期诊断及治疗，并早年在基层医院进行积极推广。熟练掌握盆腔子宫内膜异位症诊治及长期管理方案。

接诊医生：

2024-09-06 11:45:39

科普文章

子宫内膜异位症的类型与卵巢癌风险

以下内容来源于pubmed。

Endometriosis Typology and Ovarian Cancer Risk

Abstract

Importance: Endometriosis has been associated with an increased risk of ovarian cancer; however, the associations between endometriosis subtypes and ovarian cancer histotypes have not been well-described.

Objective: To evaluate the associations of endometriosis subtypes with incidence of ovarian cancer, both overall and by histotype.

Design, setting, and participants: Population-based cohort study using data from the Utah Population Database. The cohort was assembled by matching 78 893 women with endometriosis in a 1:5 ratio to women without endometriosis.

Exposures: Endometriosis cases were identified via electronic health records and categorized as superficial endometriosis, ovarian endometriomas, deep infiltrating endometriosis, or other.

Main outcomes and measures: Estimated adjusted hazard ratios (aHRs), adjusted risk differences (aRDs) per 10 000 women, and 95% CIs for overall ovarian cancer, type I ovarian cancer, and type II ovarian cancer comparing women with each type of endometriosis with women without endometriosis. Models accounted for sociodemographic factors, reproductive history, and past gynecologic operations.

Results: In this Utah-based cohort, the mean (SD) age at first endometriosis diagnosis was 36 (10) years. There were 597 women with ovarian cancer. Ovarian cancer risk was higher among women with endometriosis compared with women without endometriosis (aHR, 4.20 [95% CI, 3.59-4.91]; aRD, 9.90 [95% CI, 7.22-12.57]), and risk of type I ovarian cancer was especially high (aHR, 7.48 [95% CI, 5.80-9.65]; aRD, 7.53 [95% CI, 5.46-9.61]). Ovarian cancer risk was highest in women with deep infiltrating endometriosis and/or ovarian endometriomas for all ovarian cancers (aHR, 9.66 [95% CI, 7.77-12.00]; aRD, 26.71 [95% CI, 20.01-33.41]), type I ovarian cancer (aHR, 18.96 [95% CI, 13.78-26.08]; aRD, 19.57 [95% CI, 13.80-25.35]), and type II ovarian cancer (aHR, 3.72 [95% CI, 2.31-5.98]; aRD, 2.42 [95% CI, -0.01 to 4.85]).

Conclusions and relevance: Ovarian cancer risk was markedly increased among women with ovarian endometriomas and/or deep infiltrating endometriosis. This population may benefit from counseling regarding ovarian cancer risk and prevention and could be an important population for targeted screening and prevention studies.